The number of people living with HIV/AIDS in China is estimated to be >600,000, and projected to rise exponentially. Based on an in depth characterization of the epidemiological situation, three candidate vaccines - an innovative DNA vaccine and two different types of recombinant vaccine viruses - encoding a synthetic , Chinese clad C (CN54) derived Envy and GagPolNef polygene will be tested in a phase 1/2 clinical trial in China. 90 selected HIV negative volunteers will be vaccinated according to different prime/boost regimens and assessed for the safety and immunogenicity of the candidate vaccines. Emphasis will be put on the characterization of (cross-clade) cellular and humoral immune responses towards different regional virus strains. The proposed project also aims to establish the necessary infrastructure for future field trials.
Funding SchemeCSC - Cost-sharing contracts